Skip to content
Menu

Castle Biosciences, Inc. CSTL

Full chart Compare
Set alert

Price alert · CSTL

All alert types
33.41 USD +0.02 (+0.07%)

Regular-session close

33.41 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

33.28 Day range 34.75
18.15 52-week range 43.04
YTD
-14.13%
1 year
-3.59%

5D -2.12 (-6.04%)

333435WedThuFriMonTue32.98
Market cap
1.03B
Revenue (ttm)
377.13M
Profit margin
-6.10%
EPS (ttm)
-0.76
Shares out
30.82M
Forward P/E
-53.45
YTD return
-14.13%
1-year return
-3.59%
50-day average
34.37
200-day average
28.09
Volume
482.43K
Avg volume
383.87K
Open
33.67
Previous close
33.38
Day's range
33.28 – 34.75
52-week range
18.15 – 43.04
Beta
0.95
Analysts
Strong Buy
Price target
48.20 (+44.3%)
Earnings date
Feb 25, 2027

Key statistics

Enterprise value
787.62M
Price / sales
2.73
Price / book
2.15
Revenue growth
23.90%
Free cash flow
5.09M
Total cash
277.66M
Total debt
36.57M
Return on equity
-4.87%
Short % of float
7.01%

Fundamental scorecard

8 of 25 checks passed on CSTL’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CSTL Revenue — quarterly 102.89M
CSTL Net income — quarterly -4.10M
CSTL EPS — quarterly -0.13

Earnings

CSTL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.14———
Nov 5, 2026Sep 30, 2026-0.348-0.13+0.22+62.64%
Jul 30, 2026Jun 30, 2026-0.40697-0.07+0.34+82.80%
May 6, 2026Mar 31, 2026-0.49-0.490.000.00%
Feb 26, 2026Dec 31, 2025-0.23-0.08+0.15+65.22%
Nov 3, 2025Sep 30, 2025-0.34-0.02+0.32+94.12%

Upgrades / downgrades

CSTL analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026BairdmainOutperformOutperform
Nov 9, 2026BTIGmainBuyBuy
Nov 6, 2026KeybancmainOverweightOverweight
Aug 3, 2026BTIGmainBuyBuy
Jun 25, 2026Roth Capitalinit—Buy
May 29, 2026KeybancmainOverweightOverweight

About Castle Biosciences, Inc.

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on CSTL — it syncs with the Stock Master app.

Insider holders

CSTL insider holders
InsiderRelationLatest transactionDateShares held
BRADBURY DANIEL MDirectorConversion of Exercise of derivative securityMay 21, 202635,631
CAPLE KIMDirectorConversion of Exercise of derivative securityMay 21, 202636,121
COLE GORDON BRADLEYDirectorConversion of Exercise of derivative securityMay 21, 202632,976
COTTON RODNEYDirectorConversion of Exercise of derivative securityMay 21, 202632,998
GOLDBERG ELLENDirectorConversion of Exercise of derivative securityMay 21, 202640,921
HARRISON MILES DDirectorConversion of Exercise of derivative securityMay 21, 202635,631

Institution ownership

CSTL institution ownership
Holder% heldSharesValueReported
Blackrock Inc.11.21%3,453,715115.37MSep 29, 2026
RTW Investments LP9.02%2,778,33592.81MSep 29, 2026
Principal Financial Group, Inc.4.87%1,500,89750.14MSep 29, 2026
Portolan Capital Management, LLC4.45%1,372,87045.86MSep 29, 2026
Vanguard Capital Management LLC4.02%1,237,95141.35MSep 29, 2026
Acadian Asset Management. LLC2.86%881,86329.46MSep 29, 2026

Fund ownership

CSTL fund ownership
Holder% heldSharesValueReported
Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd.2.88%886,31729.61MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.77%852,70428.48MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.52%776,29825.93MSep 29, 2026
Principal Funds, Inc-SmallCap Fund2.35%725,13824.22MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.11%342,65511.45MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.06%327,80610.95MAug 30, 2026